메뉴 건너뛰기




Volumn 16, Issue 13, 2015, Pages 1355-1369

Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): A randomised, non-inferiority, open-label, phase 3 trial

(17)  Hegewisch Becker, Susanna a   Graeven, Ullrich b   Lerchenmüller, Christian A c   Killing, Birgitta d   Depenbusch, Reinhard e   Steffens, Claus Christoph f   Al Batran, Salah Eddin g   Lange, Thoralf h   Dietrich, Georg i   Stoehlmacher, Jan j   Tannapfel, Andrea k   Reinacher Schick, Anke l   Quidde, Julia m   Trarbach, Tanja n   Hinke, Axel o   Schmoll, Hans Joachim p   Arnold, Dirk q  


Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

EID: 84954026956     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00042-X     Document Type: Article
Times cited : (218)

References (19)
  • 1
    • 84938746812 scopus 로고    scopus 로고
    • Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systemic review and meta-analysis
    • Berry SR, Cosby R, Asmis TR, et al. Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systemic review and meta-analysis. Ann Oncol 2015, 26:477-485.
    • (2015) Ann Oncol , vol.26 , pp. 477-485
    • Berry, S.R.1    Cosby, R.2    Asmis, T.R.3
  • 2
    • 33644843853 scopus 로고    scopus 로고
    • OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a Gercor study
    • Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a Gercor study. J Clin Oncol 2006, 24:394-400.
    • (2006) J Clin Oncol , vol.24 , pp. 394-400
    • Tournigand, C.1    Cervantes, A.2    Figer, A.3
  • 3
    • 73349089651 scopus 로고    scopus 로고
    • Can chemotherapy be discontinued in unresectable metastatic cancer? The GERCOR OPTIMOX2 study
    • Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can chemotherapy be discontinued in unresectable metastatic cancer? The GERCOR OPTIMOX2 study. J Clin Oncol 2009, 27:5727-5733.
    • (2009) J Clin Oncol , vol.27 , pp. 5727-5733
    • Chibaudel, B.1    Maindrault-Goebel, F.2    Lledo, G.3
  • 4
    • 42949149159 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study
    • Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J ClinOncol 2008, 26:2013-2019.
    • (2008) J ClinOncol , vol.26 , pp. 2013-2019
    • Saltz, L.B.1    Clarke, S.2    Diaz-Rubio, E.3
  • 5
    • 80755155711 scopus 로고    scopus 로고
    • Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy-an aide et Recherche en Cancérologie Digestive Group study
    • Chibaudel B, Bonnetain F, Shi Q, et al. Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy-an aide et Recherche en Cancérologie Digestive Group study. J Clin Oncol 2011, 29:4199-4204.
    • (2011) J Clin Oncol , vol.29 , pp. 4199-4204
    • Chibaudel, B.1    Bonnetain, F.2    Shi, Q.3
  • 6
    • 84929514070 scopus 로고    scopus 로고
    • Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
    • Simkens LHJ, van Tinteren H, May AM, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015, 385:1843-1852.
    • (2015) Lancet , vol.385 , pp. 1843-1852
    • Simkens, L.H.J.1    van Tinteren, H.2    May, A.M.3
  • 7
    • 84954025962 scopus 로고    scopus 로고
    • Quality of life (QoL) in patients with metastatic colorectal cancer (MCRC) receiving maintenance therapy after first-line inductive treatment: a QoL sub-analysis of the AIO KRK 0207 phase III trial
    • (abstr)
    • Quidde J, Arnold D, Hegewisch-Becker S, et al. Quality of life (QoL) in patients with metastatic colorectal cancer (MCRC) receiving maintenance therapy after first-line inductive treatment: a QoL sub-analysis of the AIO KRK 0207 phase III trial. Ann Oncol 2014, 25:522P. (abstr).
    • (2014) Ann Oncol , vol.25 , pp. 522P
    • Quidde, J.1    Arnold, D.2    Hegewisch-Becker, S.3
  • 8
    • 84908573757 scopus 로고    scopus 로고
    • FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase3 trial
    • Heinemann V, Fischer von Weikersthal L, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase3 trial. Lancet Oncol 2014, 15:1065-1075.
    • (2014) Lancet Oncol , vol.15 , pp. 1065-1075
    • Heinemann, V.1    Fischer von Weikersthal, L.2    Decker, T.3
  • 9
    • 84937204003 scopus 로고    scopus 로고
    • CALBG/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC)
    • (abstr)
    • Lenz H, Niedzwiecki D, Innocenti F, et al. CALBG/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC). Ann Oncol 2014, 25:501O. (abstr).
    • (2014) Ann Oncol , vol.25 , pp. 501O
    • Lenz, H.1    Niedzwiecki, D.2    Innocenti, F.3
  • 10
    • 84911474269 scopus 로고    scopus 로고
    • Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up
    • Van Cutsem E, Cervantes A, Nordlinger B, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. Ann Oncol 2014, 25:iii1-iii9.
    • (2014) Ann Oncol , vol.25 , pp. iii1-iii9
    • Van Cutsem, E.1    Cervantes, A.2    Nordlinger, B.3
  • 11
    • 84926475781 scopus 로고    scopus 로고
    • Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)
    • Koeberle D, Betticher DC, Von Moos R, et al. Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Ann Oncol 2015, 26:709-714.
    • (2015) Ann Oncol , vol.26 , pp. 709-714
    • Koeberle, D.1    Betticher, D.C.2    Von Moos, R.3
  • 12
    • 84883339111 scopus 로고    scopus 로고
    • A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT trial
    • Johnsson A, Hagman H, Frödin J-E, et al. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT trial. Ann Oncol 2013, 24:2335-2341.
    • (2013) Ann Oncol , vol.24 , pp. 2335-2341
    • Johnsson, A.1    Hagman, H.2    Frödin, J.-E.3
  • 13
    • 84954029886 scopus 로고    scopus 로고
    • Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial
    • (in press).
    • Tournigand C, Chibaudel B, Samson B, et al. Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial. Lancet Oncol 2015, (in press).
    • (2015) Lancet Oncol
    • Tournigand, C.1    Chibaudel, B.2    Samson, B.3
  • 14
    • 84954026292 scopus 로고    scopus 로고
    • Immunomodulary maintenance therapy with TLR-9 agonist MGN 1703 in patients with metastatic colorectal carcinoma-the randomized phase 3 IMPALA study
    • (abstr).
    • Arnold D, Zurlo A, Salazar R, et al. Immunomodulary maintenance therapy with TLR-9 agonist MGN 1703 in patients with metastatic colorectal carcinoma-the randomized phase 3 IMPALA study. Ann Oncol 2014, 25:1077. (abstr).
    • (2014) Ann Oncol , vol.25 , pp. 1077
    • Arnold, D.1    Zurlo, A.2    Salazar, R.3
  • 15
    • 84856304557 scopus 로고    scopus 로고
    • First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study
    • Diaz-Rubio E, Gomez-Espana A, Massuti B, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 2012, 17:15-25.
    • (2012) Oncologist , vol.17 , pp. 15-25
    • Diaz-Rubio, E.1    Gomez-Espana, A.2    Massuti, B.3
  • 16
    • 84892147161 scopus 로고    scopus 로고
    • Bevacizumab and capecitabine as maintenance therapy after initial bevacizumab+XELOX treatment in previously untreated patients with metastatic colorectal cancer: Phase III stop and go study result-a Turkish Oncology Group trial
    • Yalcin S, Uslu R, Dane F, et al. Bevacizumab and capecitabine as maintenance therapy after initial bevacizumab+XELOX treatment in previously untreated patients with metastatic colorectal cancer: Phase III stop and go study result-a Turkish Oncology Group trial. Oncology 2013, 85:328-335.
    • (2013) Oncology , vol.85 , pp. 328-335
    • Yalcin, S.1    Uslu, R.2    Dane, F.3
  • 17
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    • Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
    • (2004) N Engl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3
  • 18
    • 84884700039 scopus 로고    scopus 로고
    • Bevacizumab plus capecutabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
    • Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecutabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013, 11:1077-1085.
    • (2013) Lancet Oncol , vol.11 , pp. 1077-1085
    • Cunningham, D.1    Lang, I.2    Marcuello, E.3
  • 19
    • 77955497309 scopus 로고    scopus 로고
    • Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study
    • Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010, 28:3191-3198.
    • (2010) J Clin Oncol , vol.28 , pp. 3191-3198
    • Tebbutt, N.C.1    Wilson, K.2    Gebski, V.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.